Dyne Therapeutics Scores Japan Boost; Janus Henderson CEO Sees Small-Cap Opportunity
Dyne Therapeutics Inc. (NASDAQ:DYN) has received a significant boost in Japan with the Orphan Drug designation for its DYNE-251 therapeutic. Meanwhile, Ali Dibadj, CEO of Janus Henderson Investors, shared insights on market trends in a recent CNBC interview.
Dibadj discussed the current state of the stock market today on 'Squawk Box', highlighting the securitized sector's cheap valuation and his expectation for extended duration. He noted that clients are seeking innovative companies, particularly in healthcare and tech, that can navigate geopolitical changes.
Dibadj acknowledged the dominance of a small group of companies but emphasized the opportunities in equities. He believes the broad base of small and mid-cap stocks is undervalued and has enormous potential to deliver in the future. This sentiment was echoed in a recent article listing the 10 best stocks to buy under $20, based on hedge fund popularity and analyst bullishness.
In other news, Ford Motor Company (NYSE:F) and General Motors Company (NYSE:GM) have initiated programs to extend the benefit of the expiring US federal tax credit on EV leases.
Dibadj's optimism about small and mid-cap stocks could signal a shift in investor focus, potentially benefiting companies like Dyne Therapeutics. The Orphan Drug designation in Japan may also boost Dyne's prospects. Meanwhile, Ford and GM's initiatives could stimulate EV demand, further driving the stock market's growth.
Read also:
- Eric Dane Diagnosed with ALS, Advocates for ACT for ALS
- Deepwater Horizon Oil Spill: BP Faces Record-Breaking Settlement - Dubbed 'Largest Environmental Fine Ever Imposed'
- Meta Unveils Ray-Ban AR Display Sunglasses; TikTok Agrees to $200 Million Deal
- Historic downtown temples to receive restoration funds totaling over 25 million pesos
